Suppr超能文献

鞘脂在炎症性肠病中的多种作用。

The diverse roles of sphingolipids in inflammatory bowel disease.

机构信息

School of Nutritional Sciences and Wellness, University of Arizona, Tucson, Arizona, USA.

University of Arizona Cancer Center, University of Arizona, Tucson, Arizona, USA.

出版信息

FASEB J. 2024 Jul 15;38(13):e23777. doi: 10.1096/fj.202400830R.

Abstract

The incidence of inflammatory bowel disease (IBD) has increased over the last 20 years. A variety of causes, both physiological and environmental, contribute to the initiation and progression of IBD, making disease management challenging. Current treatment options target various aspects of the immune response to dampen intestinal inflammation; however, their effectiveness at retaining remission, their side effects, and loss of response from patients over time warrant further investigation. Finding a common thread within the multitude causes of IBD is critical in developing robust treatment options. Sphingolipids are evolutionary conserved bioactive lipids universally generated in all cell types. This diverse lipid family is involved in a variety of fundamental, yet sometimes opposing, processes such as proliferation and apoptosis. Implicated as regulators in intestinal diseases, sphingolipids are a potential cornerstone in understanding IBD. Herein we will describe the role of host- and microbial-derived sphingolipids as they relate to the many factors of intestinal health and IBD.

摘要

过去 20 年来,炎症性肠病(IBD)的发病率有所上升。多种生理和环境因素导致 IBD 的发生和发展,使得疾病的管理极具挑战性。目前的治疗选择针对免疫反应的多个方面,以抑制肠道炎症;然而,它们在维持缓解、副作用以及随着时间的推移患者的反应丧失方面的有效性需要进一步研究。在 IBD 的众多病因中找到一个共同的线索对于开发强有力的治疗方法至关重要。鞘脂是进化上保守的生物活性脂质,普遍存在于所有细胞类型中。这个多样化的脂质家族参与多种基本但有时相互矛盾的过程,如增殖和凋亡。鞘脂作为肠道疾病的调节因子,是理解 IBD 的一个潜在基石。本文将描述宿主和微生物衍生的鞘脂的作用,因为它们与肠道健康和 IBD 的许多因素有关。

相似文献

1
The diverse roles of sphingolipids in inflammatory bowel disease.
FASEB J. 2024 Jul 15;38(13):e23777. doi: 10.1096/fj.202400830R.
2
Interventions for the management of abdominal pain in Crohn's disease and inflammatory bowel disease.
Cochrane Database Syst Rev. 2021 Nov 29;11(11):CD013531. doi: 10.1002/14651858.CD013531.pub2.
3
Patient education interventions for the management of inflammatory bowel disease.
Cochrane Database Syst Rev. 2023 May 4;5(5):CD013854. doi: 10.1002/14651858.CD013854.pub2.
5
Artificial intelligence in inflammatory bowel disease endoscopy - a review of current evidence and a critical perspective on future challenges.
Therap Adv Gastroenterol. 2025 Jul 13;18:17562848251350896. doi: 10.1177/17562848251350896. eCollection 2025.
6
Stem cell transplantation for induction of remission in medically refractory Crohn's disease.
Cochrane Database Syst Rev. 2022 May 13;5(5):CD013070. doi: 10.1002/14651858.CD013070.pub2.
8
Management of urinary stones by experts in stone disease (ESD 2025).
Arch Ital Urol Androl. 2025 Jun 30;97(2):14085. doi: 10.4081/aiua.2025.14085.
9
Maintenance treatment with vedolizumab in paediatric inflammatory bowel disease (VEDOKIDS): 54-week outcomes of a multicentre, prospective, cohort study.
Lancet Gastroenterol Hepatol. 2025 Mar;10(3):234-247. doi: 10.1016/S2468-1253(24)00319-4. Epub 2025 Jan 6.
10
Prostaglandins and Inflammatory Bowel Disease: From Mechanism to Clinic.
Inflamm Bowel Dis. 2025 Jun 25. doi: 10.1093/ibd/izaf121.

引用本文的文献

1
Ceramide signaling in immunity: a molecular perspective.
Lipids Health Dis. 2025 Jul 1;24(1):225. doi: 10.1186/s12944-025-02642-2.
3
Adiponectin and gastric fundus: A potential target for gut-brain axis dysfunctions.
Physiol Rep. 2025 Jun;13(11):e70398. doi: 10.14814/phy2.70398.

本文引用的文献

1
Therapeutic Potential for Sphingolipids in Inflammatory Bowel Disease and Colorectal Cancer.
Cancers (Basel). 2024 Feb 15;16(4):789. doi: 10.3390/cancers16040789.
3
Faecal metabolome and its determinants in inflammatory bowel disease.
Gut. 2023 Aug;72(8):1472-1485. doi: 10.1136/gutjnl-2022-328048. Epub 2023 Mar 23.
4
Alkaline sphingomyelinase (NPP7) impacts the homeostasis of intestinal T lymphocyte populations.
Front Immunol. 2023 Jan 19;13:1050625. doi: 10.3389/fimmu.2022.1050625. eCollection 2022.
8
Host hepatic metabolism is modulated by gut microbiota-derived sphingolipids.
Cell Host Microbe. 2022 Jun 8;30(6):798-808.e7. doi: 10.1016/j.chom.2022.05.002. Epub 2022 May 26.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验